Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Jiangsu HengRui Medicine Co., Ltd.

6 clinical trials · 6 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Jiangsu HengRui Medicine Co., Ltd.

RECRUITINGPhase 3NCT06126640

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast...

This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease...

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 16002 locations
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
RECRUITINGPhase 1 / Phase 2NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 1002 locations
Prostate Cancer
RECRUITINGPhase 1NCT06783829

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with...

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 2401 location
Prostate Cancer
RECRUITINGPhase 3NCT07238283

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line...

This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II)...

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 6621 location
First-line Treatment of Metastatic Pancreatic Cancer
RECRUITINGPhase 3NCT06596876

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed...

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 4501 location
Parkinson's Disease
RECRUITINGPhase 2NCT06775340

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

Sponsor: Jiangsu HengRui Medicine Co., Ltd.Enrolling: 2521 location
Adolescent Asthma